1 / 11

Glecaprevir - Pibrentasvir in Patients with HIV-HCV Coinfection EXPEDITION-2

Explore the results, design, and dosing of Glecaprevir-Pibrentasvir in patients with HIV-HCV coinfection, including baseline characteristics and treatment outcomes. This study offers insights into effective treatment regimens. Discover more at the University of Washington's Hepatitis C Online and Hepatitis Web Study projects.

yawn
Download Presentation

Glecaprevir - Pibrentasvir in Patients with HIV-HCV Coinfection EXPEDITION-2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Patients with HIV-HCV CoinfectionEXPEDITION-2 Source: RockstrohJK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  2. Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Study Features Source: RockstrohJK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  3. Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Study Design 0 8 12 20 24 Week GLE-PIB GT 1-6 Non-Cirrhoticn = 137 SVR12 GT 1-6 Cirrhoticn = 16 GLE-PIB SVR12 Abbreviations: GLE-PIB= Glecaprevir-pibrentasvir Drug DosingGlecaprevir-pibrentasvir(100/40 mg) fixed-dose combination: three pills (300/120 mg) once daily Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  4. Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Baseline Characteristics Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  5. Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Baseline Characteristics Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  6. Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Baseline Polymorphisms Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  7. Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Results EXPEDITION-2: Overall SVR by Analysis 150/153 150/151 ITT = Intent-to-treat; mITT = modified intent-to-treat One GT3 patient with cirrhosis and 85% compliance had on-treatment virologic failure Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  8. Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Results EXPEDITION-2: Overall SVR by Treatment Regimen 136/136* 14/15 *Excludes one patient with missing data who achieved SVR24 Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  9. Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Adverse Events Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  10. Glecaprevir-Pibrentasvir in HIV-HCV Coinfected PatientsEXPEDITION-2: Conclusions Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]

  11. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related